KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Revenue (2016 - 2025)

Rigel Pharmaceuticals has reported Revenue over the past 15 years, most recently at $69.8 million for Q4 2025.

  • Quarterly results put Revenue at $69.8 million for Q4 2025, up 21.19% from a year ago — trailing twelve months through Dec 2025 was $294.3 million (up 64.15% YoY), and the annual figure for FY2025 was $294.3 million, up 64.15%.
  • Revenue for Q4 2025 was $69.8 million at Rigel Pharmaceuticals, roughly flat from $69.5 million in the prior quarter.
  • Over the last five years, Revenue for RIGL hit a ceiling of $101.7 million in Q2 2025 and a floor of $16.7 million in Q1 2022.
  • Median Revenue over the past 5 years was $32.8 million (2022), compared with a mean of $43.0 million.
  • Biggest five-year swings in Revenue: tumbled 79.34% in 2022 and later skyrocketed 176.01% in 2025.
  • Rigel Pharmaceuticals' Revenue stood at $20.4 million in 2021, then surged by 151.25% to $51.3 million in 2022, then plummeted by 30.2% to $35.8 million in 2023, then surged by 60.92% to $57.6 million in 2024, then rose by 21.19% to $69.8 million in 2025.
  • The last three reported values for Revenue were $69.8 million (Q4 2025), $69.5 million (Q3 2025), and $101.7 million (Q2 2025) per Business Quant data.